Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 116
Filter
1.
Neoplasma ; 57(2): 184-8, 2010.
Article in English | MEDLINE | ID: mdl-20099984

ABSTRACT

Photodynamic therapy (PDT) is a treatment for cancer based on the photosensitization of tumor cells by photosensitive drugs and their subsequent destruction on exposure to light of particular wavelength. The combination of drug uptake in malignant tissues and selective delivery of laser-generated light provides an effective therapy with efficient tumor citotoxicity and minimal normal tissue damage. Since immune response of the host is important in the control of tumor growth and spreading, PDT is able to increase the antitumor immunity. In our laboratory we examined the antitumor effect of combination of PDT, with photoactivated M-THPC (meta-tetrahydroxyphenylchlorin, FOSCAN, Temoporphirin), adoptive immunotherapy, with immune lymphocytes, and chemotherapy on advanced murine tumors. Mice bearing L1210 tumor were treated at day +4 with Navelbine (NVB 1mg/Kg), at day +5,+6 with PDT (0.3mg/Kg of mTHPC and 100mW/cm(2) x 200'' of exposure of laser light), and at day + 7 with immune lymphocytes(IL), collected from mice pretreated with PDT(2x10(7) cells). The results show that the combination NVB + PDT + IL demonstrates a significant synergistic antitumor effect while the chemotherapy treatment with low dose of the drug is uneffective. The same positive results were obtained with the combination of Cisplatin (CDDP 0.5mg/Kg), PDT and IL, while the CDDP treatment alone is completely uneffective. In conclusion, these results suggest that it is possible to completely cure animals bearing advanced tumors, with a combined therapy, PDT + adoptive immunotherapy + low dose chemotherapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Immunotherapy, Adoptive , Leukemia L1210/therapy , Photochemotherapy , Animals , Combined Modality Therapy , Lasers , Leukemia L1210/immunology , Leukemia L1210/pathology , Lymphocytes/drug effects , Lymphocytes/immunology , Lymphocytes/radiation effects , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , Survival Rate
2.
Cell Signal ; 19(10): 2118-26, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17643959

ABSTRACT

Akt activation assists tumor cell survival and promotes resistance to chemotherapy. Here we show that constitutively active Akt (CA-Akt) cells are highly sensitized to cell death induced by nutrient and growth factor deprivation, whereas dominant-negative Akt (DN-Akt) cells have a high rate of survival. The content of autophagosomes in starved CA-Akt cells was high, while DN-Akt cells expressed autophagic vacuoles constitutively, independently of nutrition conditions. Thus Akt down-regulation and downstream events can induce autophagosomes which were not directly determinants of cell death. Biochemical analysis in Akt-mutated cells show that (i) Akt and mTOR proteins were degraded more rapidly than the housekeeping proteins, (ii) mTOR phosphorylation at position Thr(2446) was relatively high in DN-Akt and low in CA-Akt cells, induced by starvation in mock cells only, which suggests reduced autoregulation of these pathways in Akt-mutated cells, (iii) both protein synthesis and protein degradation were significantly higher in starved CA-Akt cells than in starved DN-Akt cells or mock cells. In conclusion, constitutively active Akt, unable to control synthesis and wasting of proteins, accelerates the death of starved cells.


Subject(s)
Apoptosis , Proto-Oncogene Proteins c-akt/metabolism , Autophagy , Cell Line , Cell Survival , Culture Media, Serum-Free , Humans , Mutation , Protein Biosynthesis , Protein Kinases/metabolism , Proteins/metabolism , Proto-Oncogene Proteins c-akt/genetics , TOR Serine-Threonine Kinases , Vacuoles/metabolism
3.
Curr Pharm Des ; 10(7): 769-84, 2004.
Article in English | MEDLINE | ID: mdl-15032702

ABSTRACT

Maneuvering single gene expression is not only an optimal way to study gene function but also an ambitious goal, which will lead to the treatment of a variety of human diseases whose main pathogenetic event is a genetic alteration. The recent efforts focusing on the genome project have led to array based, high throughput, gene expression analysis techniques that allow the study of complex molecular networks. Combining these powerful new technologies with modulation of gene expressions is making it possible to unravel complex molecular networks or, vice versa, to find new gene products responsible for pathological conditions on which exogenous modulation can be productive. Efficient and specific modulation of gene expression can be obtained either by producing transgenic or gene knockout organisms or cells (gene targeting), or by treating organisms or cells with short synthetic nucleic acid segments in antisense orientation with respect to the targeted mRNAs (mRNA targeting by antisense strategy). While genome manipulation is a time consuming and expensive approach, requiring invasive intervention, the "antisense strategy" is characterized by high flexibility resulting from safeness, specificity, reversibility, modulability, and low cost. The rationale of the antisense strategy is that, once one gene sequence is known, its expression can be silenced by application of synthetic single-strand nucleic acid segments (oligonucleotides) whose sequence is in antisense orientation compared to the targeted mRNA. Recently, this "informational" strategy has been boosted by the discovery of the RNA interference: a natural mechanism by which cells are thought to fight detrimental exogenous viruses and endogenous transposons. Despite promising futures, antisense-based therapeutics are far from being an established reality. This review analyses the recent improvements in antisense-based gene expression modulation, focuses on the treatment of diseases in the light of the past, and provides our personal findings on this topic.


Subject(s)
Oligonucleotides, Antisense/chemical synthesis , Oligonucleotides, Antisense/pharmacology , Animals , Drug Delivery Systems , Drug Design , Gene Expression/drug effects , Humans , Information Theory , Neoplasms/genetics , Neoplasms/pathology , Oligonucleotides, Antisense/administration & dosage , Structure-Activity Relationship
4.
Drugs Exp Clin Res ; 29(5-6): 257-61, 2003.
Article in English | MEDLINE | ID: mdl-15134382

ABSTRACT

In modern industrial societies the attention to public health, especially in relation to food habits, is increasing day by day. Considering this, it's no wonder that wine, the voluptuary drink that best represents human history, is the most interesting compound. The main and best known wine effects on the human body are caused by alcohol, but several other active compounds are present in wine. Above all, resveratrol is able to neutralize free radicals, which can damage DNA and may lead to cancer onset. In this study, we have indagated resveratrol anticancer action, analyzing its effects on both cell cycle and growing of human lymphoma B (DHL-4) cells. MTT colorimetric test, tripan blue dye exclusion assay, and cell cycle analysis showed that resveratrol has a dose-dependent antiproliferative and antiapoptotic action on DHL-4 cells. These results confirm resveratrol's potential therapeutic role on tumors.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Stilbenes/pharmacology , Wine , Antineoplastic Agents, Phytogenic/administration & dosage , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Humans , Resveratrol , Stilbenes/administration & dosage
5.
Oncogene ; 20(43): 6172-80, 2001 Sep 27.
Article in English | MEDLINE | ID: mdl-11593425

ABSTRACT

Rapamycin, a specific inhibitor of the serine/threonine mTOR kinase, markedly inhibited both cell growth and apoptosis in human B-cell lines. Besides arresting cells in G(1) by increasing p27(kip1), rapamycin tripled the cellular level of the BCL-2 protein. The activity was dose-dependent and specific for the p27(kip1) and BCL-2 proteins. Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process. To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis. It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin. BCL-2 phosphorylation, apoptosis and hyperdiploidy were also inhibited by rapamycin. In contrast, taxol-induced microtubule stabilization or metaphase synchronization were not inhibited by rapamycin. Taken together, these findings indicate that mTOR belongs to the enzymatic cascade that, starting from damaged microtubules, phosphorylates BCL-2. By regulating apoptosis, in addition to the control of a multitude of growth-related pathways, mTOR plays a nodal role in signaling G(1) and G(2)-M events.


Subject(s)
Microtubules/metabolism , Protein Kinases/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Tumor Suppressor Proteins , Apoptosis/drug effects , Blotting, Western , Cell Cycle/drug effects , Cell Cycle Proteins/metabolism , Cell Division , Cyclin-Dependent Kinase Inhibitor p27 , Diploidy , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Flow Cytometry , Humans , Microtubules/drug effects , Nocodazole/pharmacology , Paclitaxel/pharmacology , Phosphorylation/drug effects , RNA, Messenger/metabolism , Signal Transduction/drug effects , Sirolimus/pharmacology , TOR Serine-Threonine Kinases , Tumor Cells, Cultured
6.
Biochem Biophys Res Commun ; 287(5): 1063-9, 2001 Oct 12.
Article in English | MEDLINE | ID: mdl-11587529

ABSTRACT

The expression of genes requiring finely tuned control is regulated by a posttranscriptional mechanism involving mRNA A + U-rich elements (AREs) cooperating with ARE-binding proteins (AUBPs) in modulation of mRNA stability. We reported previously that an ARE in the bcl-2 mRNA 3'-untranslated region (3'-UTR) had destabilizing activity and was involved in bcl-2 downregulation during apoptosis in vitro. Here we demonstrate that the bcl-2 ARE complexes with a number of specific AUBPs, whose pattern undergoes changes following application of apoptotic stimuli. The caspase inhibitor Z-VAD-fmk strongly attenuates both bcl-2 mRNA decay and bcl-2 AUBP pattern changes elicited by apoptotic stimuli, indicating the involvement of bcl-2 AUBPs in bcl-2 mRNA stability control.


Subject(s)
Apoptosis , Proto-Oncogene Proteins c-bcl-2/genetics , RNA Processing, Post-Transcriptional , RNA, Messenger/metabolism , RNA-Binding Proteins/metabolism , 3' Untranslated Regions/metabolism , Amino Acid Chloromethyl Ketones/pharmacology , Caspase Inhibitors , Gene Expression Regulation , Half-Life , Humans , Jurkat Cells , Protein Binding/radiation effects , RNA Stability , Ultraviolet Rays
7.
Eur J Cancer ; 37(16): 2121-8, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11597394

ABSTRACT

The immunosuppressant rapamycin, an immunophilin-binding antibiotic, has been studied in follicular B-cell lymphoma lines that express the highest level of the BCL-2 protein. The growth rate of human follicular B-cell lymphoma lines was slowed more efficiently than that of other human B-cell lines or non-B-cell lines. This effect was dependent on the arrest of cells in the G(1) phase; the number of apoptotic cells was not increased. Rapamycin inhibited apoptosis or caspase activation induced by cytotoxic drugs, whereas caspase activation by doxorubicin was not inhibited. The increase in the cellular concentration of BCL-2 protein was related to its concentration in the steady state and was unrelated to the amount of bcl-2 mRNA. The increase of BCL-2 level in the cells rather than its level in the steady state may be important for drug resistance. The biochemical target of rapamycin, the mTOR kinase, may be a candidate sensitising agent for chemotherapy. This effect of rapamycin shows that G(1) arrest and protection from apoptosis are combined events susceptible to regulation by pharmacological means.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Apoptosis/drug effects , Lymphoma, B-Cell/pathology , Neoplasm Proteins/drug effects , Proto-Oncogene Proteins c-bcl-2/drug effects , Sirolimus/pharmacology , Caspases/metabolism , Cell Cycle/drug effects , Cell Division/drug effects , G1 Phase/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Immunosuppressive Agents/pharmacology , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/metabolism , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Tumor Cells, Cultured
8.
Nucleosides Nucleotides Nucleic Acids ; 19(8): 1273-9, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11097057

ABSTRACT

In an effort to identify potential upregulators of bcl-2 activity in t(14;18) follicular B lymphoma cells, we detected a hybrid bcl-2/IgH RNA transcribed in antisense orientation. This antisense transcript may contribute to upregulation of bcl-2 expression in t(14;18) cells, overlapping AU-rich motifs present in the 3'-untranslated region of bcl-2 mRNA. We have studied the enzymatic efficiency of a ribozyme directed towards the bcl-2 AU-rich region in a cell-free system determining its kinetic parameters.


Subject(s)
3' Untranslated Regions/genetics , Gene Expression Regulation, Neoplastic , Proto-Oncogene Proteins c-bcl-2/physiology , RNA, Antisense/genetics , Base Pairing , Burkitt Lymphoma/pathology , Cell-Free System , Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 14/ultrastructure , Chromosomes, Human, Pair 18/genetics , Chromosomes, Human, Pair 18/ultrastructure , Genes, Immunoglobulin , Humans , Immunoglobulin Heavy Chains/genetics , Kinetics , Lymphoma, Follicular/genetics , Lymphoma, Follicular/pathology , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/chemistry , RNA, Catalytic/metabolism , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Substrate Specificity , Translocation, Genetic/genetics , Tumor Cells, Cultured
9.
FASEB J ; 14(1): 174-84, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10627292

ABSTRACT

The control of mRNA stability is becoming recognized as a crucial point of gene expression regulation. A common element responsible for mRNA decay modulation is the adenine- and uracil-rich element that is found in the 3' untranslated region of numerous mRNAs subjected to fast expression changes in response to various stimuli. Previously we identified a post-transcriptional regulation level for the antiapoptotic bcl-2 gene, which could be involved in t(14;18) lymphoma-associated bcl-2 overexpression. Here we demonstrate that bcl-2 mRNA is endowed with an adenine- and uracil-rich element (ARE) characterized by high evolutionary conservation not only among all chordates examined, but even between chordates and the nematode Caenorhabditis elegans (ced-9 gene). As for other well-established destabilizing AREs, the insertion of the bcl-2 ARE downstream from stable beta-globin mRNA causes an enhanced decay of the beta-globin transcript, which proves its functional role. This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. Conversely, it is noteworthy that when C(2)-ceramide is added to the culture medium as the apoptotic agent, the beta-globin transcript harboring the bcl-2 ARE undergoes a dramatic increase in decay. This observation clearly indicates that the destabilizing function of bcl-2 ARE is enhanced by apoptotic stimuli and suggests that this element could be involved in a post-transcriptional mechanism of bcl-2 down-regulation during apoptosis. The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C(2)-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. Thus, this element becomes a new candidate for mediating those bcl-2 gene expression changes-from apoptosis-associated down-regulation to tumor-associated overexpression-observed thus far that profoundly influence single cell fate and tissue homeostasis.


Subject(s)
3' Untranslated Regions , Apoptosis/genetics , Down-Regulation/genetics , Genes, bcl-2 , RNA, Messenger/genetics , 3T3 Cells , Adenine/analysis , Animals , Base Sequence , DNA Primers , Evolution, Molecular , Mice , Molecular Sequence Data , Protein Kinase C/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Uracil/analysis
10.
Cancer Lett ; 125(1-2): 39-44, 1998 Mar 13.
Article in English | MEDLINE | ID: mdl-9566694

ABSTRACT

Photodynamic therapy (PDT) is based on the administration of tumor-localizing photosensitizers followed by light exposure of the tumor mass. The photocytotoxic effects are mainly caused by the generation of singlet oxygen. Recently, PDT has been proposed for use in combination with anticancer chemotherapy with a view to exploiting any additive antitumor effect. We investigated the effect of PDT with photoactivated aluminum disulfonated phthalocyanine (AlS2Pc) combined with the antiblastic drugs Adriamycin (ADR) and cisplatinum (CDDP) on murine tumors. Mice bearing L1210 leukemia and P388 lymphoma were treated with ADR or CDDP and subsequently treated with PDT. Low chemotherapy doses were ineffective, but the combination of antiblastic drugs + PDT had a significantly additive antitumor effect. In conclusion, with this combined therapy we were able to greatly reduce the effective doses of antiblastic drugs, thus lowering their toxic effects on normal host tissues.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , Doxorubicin/therapeutic use , Neoplasms, Experimental/drug therapy , Photochemotherapy , Animals , Combined Modality Therapy , Male , Mice , Mice, Inbred BALB C , Mice, Inbred DBA
11.
Eur J Pharmacol ; 330(1): 15-25, 1997 Jul 02.
Article in English | MEDLINE | ID: mdl-9228410

ABSTRACT

The effect of an antisense oligonucleotide to the K+ channel coding mKv1.1 mRNA on antinociception induced by the tricyclic antidepressants, clomipramine (20-35 mg kg(-1) s.c.) and amitriptyline (10-25 mg kg(-1) s.c.), was investigated in the mouse hot-plate test. Antisense oligonucleotide (0.5-1.0-2.0-3.0 nmol per i.c.v. injection) produced a dose-dependent inhibition of clomipramine and amitriptyline antinociception 72 h after the last i.c.v. injection. The sensitivity to both analgesic drugs returned 7 days after antisense oligonucleotide injection, indicating the absence of irreversible damage or toxicity. Treatment with a degenerated oligonucleotide did not modify the clomipramine- and amitriptyline-induced antinociception in comparison with that in naive (unpretreated controls), vector and saline i.c.v.-injected mice. A quantitative reverse transcription-polymerase chain reaction (RT-PCR) study demonstrated a reduction in mRNA levels only in the antisense oligonucleotide treated group. Antisense oligonucleotide, degenerated oligonucleotide or vector pretreatment, in the range of doses used, did not produce any behavioural impairment as revealed by the mouse rotarod and hole-board tests. The present results indicate that modulation of the mKv1.1 K+ channel plays an important role in the central analgesia induced by the tricyclic antidepressants, clomipramine and amitriptyline.


Subject(s)
Amitriptyline/pharmacology , Clomipramine/pharmacology , Oligonucleotides, Antisense/pharmacology , Pain Threshold/drug effects , Potassium Channels/genetics , Amitriptyline/antagonists & inhibitors , Animals , Brain Chemistry/drug effects , Clomipramine/antagonists & inhibitors , Male , Mice , Molecular Sequence Data , Motor Activity/drug effects , Pain Measurement , Polymerase Chain Reaction , Potassium Channels/drug effects , RNA, Messenger/analysis , Sequence Homology , Virulence Factors, Bordetella/pharmacology
12.
Proc Natl Acad Sci U S A ; 94(15): 8150-5, 1997 Jul 22.
Article in English | MEDLINE | ID: mdl-9223330

ABSTRACT

In most human follicular B cell lymphomas the bcl-2 gene is up-regulated as a result of the t(14;18) chromosomal translocation generating a hybrid bcl-2-IgH mRNA. Recently, we have identified in t(14;18)-positive cells a bcl-2-IgH mRNA in the antisense orientation, putatively responsible for the overexpression of bcl-2. Herein we show that this chimeric antisense transcript is an optimal target for synthetic oligodeoxynucleotides (ODNs). A variety of sense-oriented oligonucleotides have been designed that target the antisense transcript in regions endowed with a sequence specificity presumably restricted to an individual cell line (the bcl-2-IgH fusion regions) or extended to all t(14;18) cells (the ectopic bcl-2 segment upstream from the major breakpoint region and the IgH segment). All sense-oriented ODNs complementary to the antisense transcript induced an early strong inhibition of cell growth and a late fulminant cell death. As expected, the activity of ODNs targeting the fusion region was restricted to each individual cell line, whereas the activity of all ODNs targeting the common bcl-2 and IgH segments was extended to all t(14;18) cell lines tested. These sense ODNs were not effective in untranslocated cell lines. Antisense-oriented ODNs, complementary to the bcl-2-IgH mRNA, and control ODNs (scrambled, inverted, or mismatched) were biologically ineffective. The selectivity and efficacy of all sense ODNs tested provide support for the development of therapeutic ODNs targeting the bcl-2-IgH antisense transcript expressed in human follicular lymphomas.


Subject(s)
Immunoglobulin Heavy Chains/genetics , Oligonucleotides/pharmacology , Proto-Oncogene Proteins c-bcl-2/genetics , RNA, Antisense/drug effects , RNA, Messenger/drug effects , Apoptosis/drug effects , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 18 , Humans , Translocation, Genetic , Tumor Cells, Cultured
13.
Oncogene ; 13(1): 105-15, 1996 Jul 04.
Article in English | MEDLINE | ID: mdl-8700536

ABSTRACT

The 14;18 chromosome translocation, characteristic of most human follicular B-cell lymphomas, juxtaposes the bcl-2 gene with the IgH locus, creating a bcl-2/IgH hybrid gene. By mechanisms that are still under investigation, this event increases the cellular levels of the bcl-2 mRNA and thereby induces an overproduction of the antiapoptotic BCL-2 protein which is likely responsible for neoplastic transformation. In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion. This antisense transcript is a hybrid bc1-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and spans at least the complete 3' UTR region of the bcl-2 mRNA. To achieve some insight into its biological function, we treated the t(14;18) DOHH2 cell line with oligonucleotides (ODNs) by specifically targeting the bc1-2/IgH antisense strand. These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis. We would like to propose the hypothesis that the bc1-2/IgH antisense transcript may contribute, by an unknown mechanism, to upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.


Subject(s)
Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 18/genetics , Gene Expression Regulation, Neoplastic/physiology , Genes, Immunoglobulin , Immunoglobulin Heavy Chains/genetics , Lymphoma, Follicular/genetics , Neoplasm Proteins/genetics , Proto-Oncogene Proteins/genetics , RNA, Antisense/genetics , Translocation, Genetic , Apoptosis/genetics , Base Sequence , Burkitt Lymphoma/genetics , Burkitt Lymphoma/pathology , Enhancer Elements, Genetic , Humans , Leukemia-Lymphoma, Adult T-Cell/genetics , Leukemia-Lymphoma, Adult T-Cell/pathology , Molecular Sequence Data , Neoplasm Proteins/biosynthesis , Polymerase Chain Reaction , Promoter Regions, Genetic , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins c-bcl-2 , Transcription, Genetic , Tumor Cells, Cultured
14.
Anticancer Drugs ; 7(2): 189-94, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8740724

ABSTRACT

An oligodeoxynucleotide (ODN), capable of reducing the growth of human B lymphocytes carrying the t(14;18) chromosome translocation, was prepared in different 'chemical versions': unmodified phosphodiester, phosphorothioate and phosphodiester capped with L-2'-deoxycytidine. Their binding affinity to the complementary synthetic target was studied by the melting point assay. The ODNs, administered to DOHH2 cells, were compared for stability in the culture medium, cellular uptake, time course of the intact sequence concentration within the cell and ability to inhibit cell growth. The 5', 3'-L-capped derivative and the phosphorothioate had comparable potency, superior to that of the unmodified ODN, in agreement with the concentration of undegraded ODNs within the cell.


Subject(s)
Antineoplastic Agents/pharmacology , Oligonucleotides/chemistry , Oligonucleotides/pharmacology , Antineoplastic Agents/chemistry , Cell Division/drug effects , Densitometry , Drug Stability , Humans , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/pathology , Oligonucleotides/metabolism , Temperature , Thionucleotides/chemistry , Thionucleotides/pharmacology , Time Factors , Tumor Cells, Cultured , Ultraviolet Rays
15.
Article in English | MEDLINE | ID: mdl-8783795

ABSTRACT

Three techniques are evaluated for assessing the purity of synthetic oligodeoxyribonucleotides: reversed phase high-performance liquid chromatography (RP-HPLC), polyacrylamide gel-slab electrophoresis (PAGE), and capillary zone electrophoresis highly concentrated (18% T) entangled polymer networks (CZE). RP-HPLC does not seem to be able to discriminate and resolve the spectrum of failed sequences expected to accompany an oligonucleotide of a given length. The purity data, as given by the manufacturer, are most often close to 100%. PAGE in 20% T matrices, followed by ethidium bromide staining, gives a good resolution of failure sequences and purity assessments decidedly more realistic. CZE in 18% liquid polyacrylamide is able to resolve to baseline all shorter fragments and to give a precise evaluation of the amount of impurities, based on the intrinsic DNA absorbance at 254 nm. Most of the 18 mer oligonucleotides (and of their phosphorothioate derivatives) analyzed by us, as supplied by three different manufacturers, were found to be contaminated by a spectrum of failed and truncated sequences, ranging in size from 7 mer to 17 mer. The purity data rarely exceeded 80% and most often were of the order of 60%-70%. Conditions for a good routine performance of the CZE technique are described.


Subject(s)
Oligonucleotides, Antisense/analysis , Base Sequence , Capillary Action , Chromatography, High Pressure Liquid/methods , Coloring Agents , Drug Contamination , Electrophoresis, Polyacrylamide Gel/methods , Ethidium , Oligonucleotides, Antisense/chemistry , Thionucleotides
16.
Antisense Nucleic Acid Drug Dev ; 6(2): 95-101, 1996.
Article in English | MEDLINE | ID: mdl-8843323

ABSTRACT

The antiproliferative effects mediated by a 14-mer homopyrimidine oligonucleotide (5' CTTTCT-CTTTTCTC3'), designed to form DNA triplex with a purine region of the DNA polymerase alpha promoter, were evaluated on the human breast cancer cell line MDA-MB 231. In order to stabilize the triple complex under physiologic conditions, replacement of cytosines by methylcytosines in the oligomer sequence was carried out. Band-shift analyses demonstrated a complete triplex formation between the radiolabeled target duplex DNA and the methylcytosine-modified oligomer at the concentration of 0.1 microM under physiologic pH and temperature. A single exposure of MDA-MB 231 cells to 0.5 microM methylcytosine-modified oligonucleotide was able to markedly reduce the cell number and the percentage of cells in DNA synthesis up to 58% and 66%, respectively, compared with controls. Furthermore, a 48% reduction in the amount of the DNA polymerase alpha mRNA was reported after treatment with the oligomer. In conclusion, data from the present study demonstrate that an oligonucleotide to DNA polymerase alpha promoter, designed to form a triple helix with target double-stranded DNA, inhibits the expression of the reporter gene at the biologic and molecular levels, suggesting a possible triplex-mediated mechanism of action.


Subject(s)
DNA Polymerase II/drug effects , Oligonucleotides/pharmacology , Base Sequence , Breast Neoplasms/pathology , Cell Division/drug effects , DNA Polymerase II/biosynthesis , DNA Polymerase II/genetics , Female , Humans , Molecular Sequence Data , Oligonucleotides/genetics , Protein Binding , Protein Folding , Tumor Cells, Cultured
18.
Anticancer Drug Des ; 11(1): 1-14, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8639245

ABSTRACT

Most human follicular B-cell lymphomas are associated with t(14;18) chromosome translocation that joins the bcl-2 gene with the IgH locus. This hybrid gene causes upregulation of BCL-2 protein expression, endowing cells with survival advantage. Although early BCL-2 overexpression is definitely responsible for immortalization/transformation, its exact role in the overt transformation as well as in the maintenance of the tumor phenotype is not known. The capacity of oligodeoxynucleotides (ODN) to modulate gene expression specifically has been exploited to downregulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B-cell lymphoma line by the use of sense ODN or antisense ODN or antisense ODN designed to encompass the unique nucleotide sequence in the fusion region of the hybrid transcript. The specific downregulation of the bcl-2 transcript and of the relevant BCL-2 protein in the treated cells activated programed cell death and inhibited growing cells. The antitumor activity was restricted to the DHL-4 cell line carrying the specific nucleotide sequence at the bcl-2/IgH joining region. Thus, DHL-4 lymphoma cells derived from the acute phase of human follicular B-cell lymphoma, although endowed with additional activated oncogenes, were growth inhibited by bcl-2 downregulation with additional activated oncogenes, were growth inhibited by bcl-2 downregulation in a genetically restricted fashion. The biological activity was exerted exclusively by ODNs synthesized in the sense orientation. The sense ODNs have been proposed to anneal the hybrid bcl-2/IgH antisense RNA as identified in this study.


Subject(s)
Apoptosis , Proto-Oncogene Proteins/genetics , Amino Acid Sequence , Base Sequence , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 18 , DNA Damage , DNA Primers/chemistry , Gene Expression Regulation, Neoplastic , Genes, Immunoglobulin , Humans , Molecular Sequence Data , Proto-Oncogene Proteins c-bcl-2 , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Translocation, Genetic , Tumor Cells, Cultured
19.
Haematologica ; 80(6): 495-504, 1995.
Article in English | MEDLINE | ID: mdl-8647513

ABSTRACT

BACKGROUND: The bcl-2 gene, isolated from the t(14;18) chromosomal translocation breakpoint, is able to prevent apoptotic death induced by various stimuli in different tissues. Therefore bcl-2 oncogene expression could be a key parameter for investigating the molecular mechanisms involved in the apoptosis of normal and neoplastic hematopoietic cells. METHODS: In order to evaluate bcl-2 expression in both follicular B-lymphomas carrying or not carrying the 14;18 translocation and in lymphatic leukemias, we optimized an internal standard-based method of reverse transcriptase-polymerase chain reaction (RT-PCR) for the rapid quantitation of bcl-2 mRNA cellular levels. A simple purification of the reverse transcription products resulted in very high PCR efficiency, so that radioactive labelling of the amplification products was avoided. RESULTS: bcl-2 mRNA levels proved to be higher in t(14;18) than in t(14;18) negative cell lines, and higher in primary leukemia pre-B cells than in early-B cells. Tested for sensitivity by identifying minimal residual t(14;18) B cells expressing the bcl-2/IgH gene, this RT-PCR method was able to detect bcl-2/IgH mRNA from just one t(14;18) positive cell out of ten million t(14;18) negative cells. CONCLUSIONS: The RT-PCR method we optimized appears to be suitable for clinical use in both leukemia/lymphoma characterization and in lymphomatous disease follow-up.


Subject(s)
Gene Expression Regulation, Neoplastic/physiology , Leukemia, B-Cell/genetics , Lymphoma, B-Cell/genetics , Oncogenes , Base Sequence , Humans , Leukemia, B-Cell/pathology , Lymphoma, B-Cell/pathology , Molecular Sequence Data , Polymerase Chain Reaction/methods , RNA-Directed DNA Polymerase , Tumor Cells, Cultured
20.
Cancer Lett ; 93(2): 255-9, 1995 Jul 13.
Article in English | MEDLINE | ID: mdl-7621437

ABSTRACT

Photodynamic therapy (PDT) is a relatively new cancer treatment modality that employs light excitation of a photosensitizer to yield cytotoxic oxygen-related species. In the present study we explored whether PDT would have therapeutic effect against doxorubicin-resistant murine tumors. We compared the efficacy of PDT with aluminium disulphonated phthalocyanine (A1S2Pc) and laser light on the doxorubicin-sensitive murine tumors, B16 melanoma (B16), L1210 leukemia (L1210), P388 lymphoma (P388) and the corresponding doxorubicin-resistant lines (B16/Dx, L1210/Dx and P388/Dx). Mice bearing L1210-L1210/Dx, P388-P388/Dx and B16-B16/Dx, were treated with 5 mg/kg of A1S2Pc and laser light (100 mW/cm2 x 10 min of exposure) or with doxorubicin (10 or 12 mg/kg i.v.). The results show that PDT is active versus all tumors while doxorubicin is effective only against the three sensitive tumor lines (L1210, P388 and B16). These observations suggest that PDT might be a beneficial alternative treatment for drug-resistant tumors.


Subject(s)
Doxorubicin/therapeutic use , Indoles/therapeutic use , Neoplasms, Experimental/drug therapy , Organometallic Compounds/therapeutic use , Photochemotherapy , Animals , Drug Resistance , Leukemia L1210/drug therapy , Lymphoma/drug therapy , Melanoma, Experimental/drug therapy , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred DBA
SELECTION OF CITATIONS
SEARCH DETAIL
...